La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cadrenal Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cadrenal Therapeutics..

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Catena delle Opzioni

CADRENAL THERAPEUTICS INC

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Stifel analyst Paul Forward initiates coverage on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Buy rating and announces Price Target of $56.

News

Price Target

Initiation

Analyst Ratings

Stifel Initiates Coverage On Freeport-McMoRan with Buy Rating, Announces Price Target of $56

<ul>
<li>TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV)&nbsp;vaccine offering broad protection against H3N2 and H3N8.</li>
<li>100% virus neutralization against 33 current field isolates.</li>
<li>Unlike currently available products, only&nbsp;TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.</li>
<li>TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.</li>
</ul>
GREENFIELD, Ind., July 9, 2025 /PRNewswire/ --&nbsp;Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines made with PureFil&#x2122; Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experiences.
In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs:
<ul>
<li>Zero vaccinated dogs developed lung lesions post H3N2 challenge</li>
<li>100% neutralization of 33 currently circulating CIV field isolates</li>
<li>Proven to reduce viral shedding</li>
<li>Proven safe across multiple breed and ages in field safety study</li>
</ul>
The approval of TruCan Ultra CIV is a key addition to completing Elanco's vaccine portfolio by addressing respiratory disease outbreaks. TruCan Ultra CIV is now available for pre-order and will ship within the next 30 business days.

ELAN

Elanco Animal Health Receives USDA Approval For Trucan Ultra CIV H3N2/H3N8, Canine Influenza Vaccine To Provide Broad Respiratory Disease Protection

WIIM

EVOK

Evoke Pharma shares are trading higher after the company announced it received a notice of allowance for the U.S. patent application covering GIMOTI in patients with moderate to severe symptoms of Gastroparesis.

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect&#x2122; product line for assessing symptomatic patients
SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4464498-1&amp;h=2423927372&amp;u=https%3A%2F%2Fwww.fujirebio.com%2Fen-us%2Fnews-events%2Ffujirebio-receives-marketing-clearance-for-lumipulser-g-ptau-217bamyloid-142-plasma-0&amp;a=Lumipulse%C2%AE+G+pTau+217%2F%CE%B2-Amyloid+1-42+Plasma+Ratio">Lumipulse&#xAE; G pTau 217/β-Amyloid 1-42 Plasma Ratio</a>&nbsp;in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.
Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline.
Through its AD-Detect&#x2122; portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings.
Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.

Quest Diagnostics Plans To Offer Laboratory Testing Based On Lumipulse G pTau 217/Β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test From Fujirebio

Piper Sandler analyst David Westenberg initiates coverage on GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) with a Overweight rating and announces Price Target of $110.

Piper Sandler Initiates Coverage On GeneDx Holdings with Overweight Rating, Announces Price Target of $110

ARTL

Artelo Biosciences shares are trading higher after the company announced it presented preclinical data for ART26.12 at the 35th Annual ICRS Symposium.

Piper Sandler initiates coverage on Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Overweight rating and announces Price Target of $5.

Piper Sandler Initiates Coverage On Inovio Pharmaceuticals with Overweight Rating, Announces Price Target of $5

KIDZ

Classover Holdings shares are trading higher after the company announced it increased its Solana holdings by 295%.

UBS analyst Dan Leonard downgrades Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) from Buy to Neutral and lowers the price target from $500 to $460.

Downgrades

UBS Downgrades Thermo Fisher Scientific to Neutral, Lowers Price Target to $460

KZIA

Kazia Therapeutics shares are trading higher after the company announced preliminary results from its Phase 1b trial combining Paxalisib, Pembrolizumab, and standard chemotherapy.

Wedbush analyst Daniel Ives reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and maintains $270 price target.

Reiteration

AAPL

Wedbush Reiterates Outperform on Apple, Maintains $270 Price Target

Piper Sandler analyst Justin Crowley assumes FVCBankcorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FVCB#NASDAQ">FVCB</a>) with a Overweight rating and announces Price Target of $16.

FVCB

Piper Sandler Assumes FVCBankcorp at Overweight, Announces Price Target of $16

Eye-Net's&nbsp;V2X collision prevention technology is scheduled for live trial with 10,000 participants in the fourth quarter of 2025
Ness Ziona, Israel, July 09, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) ("Foresight" or the "Company"), an innovator in 3D perception systems, announced that its wholly-owned subsidiary, Eye-Net Mobile Ltd. ("Eye-Net"), has successfully completed the first phase of a landmark mobility trial in Bordeaux, France. The trial involved a mobile app developed by Orange S.A., one of the world's leading telecommunications companies, alongside other urban applications as part of Eye-Net's collaboration with Software République. This follows the agreement with Software République to enable smart mobility solutions for efficient urban mobility in France, as announced by the Company on November 27, 2024.
The Bordeaux trial, conducted in collaboration with Renault Group, Orange S.A., Keolis Bordeaux Métropole Mobilité, Bordeaux INP, Allianz SE and Eviden, aims to address the evolving challenges of urban mobility and represents a significant step forward in the Eye-Net's mission to enhance road safety for all urban road users, including drivers, cyclists, and pedestrians.
In the first phase, Eye-Net's vehicle-to-everything (V2X) platform was integrated into Orange's mobile app and was deployed in real-world urban settings in Bordeaux, including interactions between cyclists, passenger vehicles and buses. Using widely available smartphones and connected vehicles, Eye-Net's technology creates a real-time communication network that can detect potential collisions and deliver immediate alerts, even in situations with limited or obstructed visibility.
The second phase of the trial is planned for the fourth quarter of 2025 and will involve up to 10,000 participants using a public transportation app. During this phase, Eye-Net's alert system will be tested in live urban environments, focusing on scenarios involving cyclists and buses.
Eye-Net's solution achieved an impressive detection rate, successfully detecting more than 99% of interactions between users. Eye-Net's technology demonstrated robust interoperability, integrating smoothly with collaboration applications and data providers through its software development kit (SDK). Beyond technical performance, the trial provided valuable insights into user experience and expectations. Cyclists reported increased confidence when navigating busy urban routes, while drivers appreciated the added layer of awareness provided by real-time alerts.

FRSX

Foresight's Eye-Net Mobile Completes First Phase Of Mobility Trial In Bordeaux, France; Eye-Net's V2X Collision Prevention Technology Is Scheduled For Live Trial With 10K Participants In Q4 2025

Citigroup analyst Ariel Rosa downgrades XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) from Buy to Neutral and raises the price target from $137 to $140.

Citigroup Downgrades XPO to Neutral, Raises Price Target to $140

Citigroup analyst Ariel Rosa downgrades Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) from Buy to Neutral and raises the price target from $259 to $288.

Citigroup Downgrades Norfolk Southern to Neutral, Raises Price Target to $288

Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/BAC/earnings">opening bell on Wednesday, July 16.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at 87 cents per share, up from 83 cents per share in the year-ago period. Bank of America projects to report quarterly revenue at $26.77 billion, compared to $25.38 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 1, the company plans to increase its quarterly dividend by 8% to 28 cents per share.
Bank of America shares fell 3.1% to close at $47.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/bac/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>HSBC analyst Saul Martinez downgraded the stock from Buy to Hold and raised the price target from $47 to $51 on July 8, 2025. This analyst has an accuracy rate of 69%.</li>
<li>RBC Capital analyst Gerard Cassidy maintained an Outperform rating and increased the price target from $45 to $53 on June 30, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Baird analyst David George downgraded the stock from Outperform to Neutral with a price target of $52 on June 27, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Keith Horowitz maintained a Buy rating and raised the price target from $50 to $54 on June 26, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Goldman Sachs analyst Richard Ramsden maintained a Buy rating and boosted the price target from $46 to $52 on June 10, 2025. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying BAC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/bac/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08222627/image-86-1024x587.png" alt="" class="wp-image-977412" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08222627/image-86-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08222627/image-86-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08222627/image-86-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08222627/image-86.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Bank of America Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

-Amended Complaints Assert new high bandwidth memory (HBM) patent for AI computing and DDR5 DIMM patent-
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 9, 2025 / Netlist, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NLST#OTCQB">NLST</a>) today announced it has amended its complaints in its recently filed actions against Samsung and Micron in the U.S. District Court for the Eastern District of Texas. The two actions were originally filed on May 20, 2025, to assert Netlist's new U.S. Patent No. 12,308,087 ("the '087 patent") against Samsung's and Micron's High-Bandwidth Memory (HBM) products. The amended complaints add another Netlist patent, U.S. Patent No. 10,025,731 ("the '731 Patent"), against the two Defendants' DDR5 DIMM products, as well as their distributor Avnet, Inc. to these actions.
C.K. Hong, Netlist's Chief Executive Officer, said, "Netlist continues to expand its portfolio of patented HBM and AI-memory technologies. The amended action broadens our efforts to prevent Samsung and Micron from continued unauthorized use of Netlist's intellectual property without a license."
Netlist's ‘087 patent entitled "Memory Package Having Stacked Array Dies and Reduced Driver Load" covers HBM for current and future AI applications. Analysts currently project U.S. HBM revenues to exceed $25 billion annually for each Samsung and Micron by 2031. The ‘087 patent will expire in November 2031. Netlist's ‘731 patent reads on DDR5 DIMM with DFE and ODT/RTT circuits. Analysts currently project U.S. DDR5 DIMM revenue to exceed $65 billion annually in 2029. The ‘731 patent will expire in July 2029.
During the past two years, Netlist has obtained jury verdicts awarding combined total damages of $866 million for the willful infringement of its patents by Samsung and Micron.
Netlist is represented by Irell &amp; Manella LLP, with the legal team led by Jason Sheasby.

Legal

NLST

SSNLF

Netlist Expands Patent Infringement Lawsuits Against Samsung And Micron To Include New HBM And DDR5 DIMM Patents For AI And Memory Technologies

AEHR

Aehr Test Systems shares are trading lower following a Q4 sales miss.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 9.64%</li>
<li>BMO Capital analyst John McNulty downgraded the stock from Market Perform to Underperform and cut the price target from $29 to $22 on June 23, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Fermium Research analyst Frank Mitsch downgraded the stock from Buy to Hold with a price target of $30 on June 23, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On July 7, Dow announced it will shut down three European plants, which may result in up to $790 million worth of asset write-downs.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709">latest DOW news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709"><img loading="lazy" decoding="async" width="910" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013614/image-94.png" alt="" class="wp-image-977630" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013614/image-94.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013614/image-94-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013614/image-94-768x710.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.87%</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and cut the price target from $22 to $20 on May 5, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight and cut the price target from $17 to $13 on May 5, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: Huntsman will hold a conference call on Friday, Aug. 1, to discuss its second quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest HUN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709"><img loading="lazy" decoding="async" width="915" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013645/image-95.png" alt="" class="wp-image-977633" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013645/image-95.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013645/image-95-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013645/image-95-768x703.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.36%</li>
<li>Barclays analyst Benjamin Theurer maintained an Overweight rating and raised the price target from $48 to $49 on July 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Keybanc analyst Aleksey Yefremov maintained an Overweight rating and raised the price target from $49 to $53 on May 2, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: FMC will release its second quarter earnings on Wednesday, July 30.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest FMC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0709"><img loading="lazy" decoding="async" width="906" height="856" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013718/image-96.png" alt="" class="wp-image-977635" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013718/image-96.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013718/image-96-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09013718/image-96-768x726.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Wall Street's Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 5% Dividend Yields

Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is currently in Phase 10 of its 18-phase Adhishthana Cycle on the monthly chart, and the timing suggests it may be approaching a critical inflection point. Here&#8217;s how the structure lines up through the Adhishthana Principles.
<h3 class="wp-block-heading">A Rally in Line With the Principles</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1052" height="876" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09083530/Jabil-Monthly-Chart.png" alt="Fig.1 Jabil Inc. Monthly Chart (Source: Adhishthana.com)" class="wp-image-15530" style="width:653px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09083530/Jabil-Monthly-Chart.png 1052w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09083530/Jabil-Monthly-Chart-300x250.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09083530/Jabil-Monthly-Chart-1024x853.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09083530/Jabil-Monthly-Chart-768x640.png 768w" sizes="(max-width: 1052px) 100vw, 1052px" /><figcaption class="wp-element-caption">Fig.1 Jabil Inc. Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
Since early 2021, Jabil has staged a remarkable rally, from the $30–$50 range to now trading above $220. This move has followed the Adhishthana structure closely, particularly as the stock entered Phase 9.
According to the principles, Phase 9 marks a breakout from the Adhishthana Cakra, a channel typically formed between Phases 4 and 8. This breakout also marks the start of what is known as the Adhishthana Himalayan Formation. Jabil followed this precisely, breaking out of the Cakra and climbing over 210% in its Phase 9.
The ascent has continued into Phase 10, and while this phase can still support bullish momentum, it also opens the door for a peak to form.&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"The 18th interval is expected to be the level of peak formation; if not, then the 23rd interval. If this phase concludes without forming the peak, it is anticipated to occur in the following phases." -Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy&nbsp;
</blockquote>
This window of peak formation translates to September 2025 to February 2026, a time zone investors should now be watching closely.
<h3 class="wp-block-heading">Weekly Chart Adds to the Concern</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="505" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09082547/JBL-Cakra-Weekly-Adhishthana.png" alt="Fig.2 Jabil Inc. Cakra Formation (Source: Adhishthana.com)" class="wp-image-15529" style="width:615px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09082547/JBL-Cakra-Weekly-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09082547/JBL-Cakra-Weekly-Adhishthana-300x126.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09082547/JBL-Cakra-Weekly-Adhishthana-1024x431.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09082547/JBL-Cakra-Weekly-Adhishthana-768x323.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 Jabil Inc. Cakra Formation (Source: Adhishthana.com)</figcaption></figure>
The weekly chart echoes the cautious tone. Jabil has just entered Phase 7, which, based on the principles, is associated with the Fall of Artah and Artharthi, a two-fold correction that typically unfolds over eight red bars.
This fall targets the Level of Nirvana, which is established during Phase 6, and in Jabil's case, it was established at $137.235.
Currently, the stock is trading above its Cakra channel on the weekly chart—a signal that the price may be overextended in the short term. This misalignment with the typical channel behavior adds to the possibility that a near-term correction is on the horizon.
<h3 class="wp-block-heading">Investor Outlook</h3>
Jabil's long-term structure remains intact, but signs are emerging that a peak could form soon, possibly within the September 2025 to February 2026 time zone. Existing holders should keep a close eye on the structure. If the weekly channel breaks, it could signal the start of a larger correction phase. Preparing protective strategies or tightening risk controls would be prudent at this stage.
New investors may want to hold off on chasing this rally. With both weekly and monthly timeframes pointing toward consolidation or a potential peak, this may not be the most favorable entry point.

Equities

Technicals

Opinion

Signals

Jabil Stock Nears Key Timing Zone: Is A Peak Forming?

Press Releases

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Comments

Cadrenal Therapeutics

Cadrenal Therapeutics (CVKD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO